ReviewAntibiotics (Basel, Switzerland)2023
Real-Time Monitoring of Antibiotics in the Critically Ill Using Biosensors.
Review in Antibiotics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 17 citations in OpenAlex.
- The evolution of next-generation lateral flow assays for bacterial and fungal diagnostics.Mikrochimica acta · 2026Review
- Therapeutic Drug Monitoring and Point-of-Care Technologies: Opportunities and Current Challenges.Therapeutic drug monitoring · 2026Review
- Safe Meat, Smart Science: Biotechnology's Role in Antibiotic Residue Removal.Antibiotics (Basel, Switzerland) · 2025Review
- Dose individualisation of antibiotics in critically ill patients with inflammation: A narrative review.British journal of clinical pharmacology · 2025Review
- Conformational change-based electrochemical biosensor for the simple and highly selective detection of miRNA in whole serum.RSC advances · 2025Article
- Dose Individualisation of Antimicrobials from a Pharmacometric Standpoint: The Current Landscape.Drugs · 2024Review
- Implications of Artificial Intelligence in Addressing Antimicrobial Resistance: Innovations, Global Challenges, and Healthcare's Future.Antibiotics (Basel, Switzerland) · 2024Article
- Therapeutic Drug Monitoring and Biomarkers; towards Better Dosing of Antimicrobial Therapy.Pharmaceutics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
By ensuring optimal dosing, therapeutic drug monitoring (TDM) improves outcomes in critically ill patients by maximizing effectiveness while minimizing toxicity. Current methods for measuring plasma drug concentrations, however, can be challenging, time-consuming, and slow to return an answer, limiting the extent to which TDM is used to optimize drug exposure. A potentially promising solution to this dilemma is provided by biosensors, molecular sensing devices that employ biorecognition elements to recognize and quantify their target molecules rapidly and in a single step. This paper reviews the current state of the art for biosensors regarding their application to TDM of antibiotics in the critically ill, both as ex vivo point-of-care devices supporting single timepoint measurements and in vivo devices supporting continuous real-time monitoring in situ in the body. This paper also discusses the clinical development of biosensors for TDM, including regulatory challenges and the need for standardized performance evaluation. We conclude by arguing that, through precise and real-time monitoring of antibiotics, the application of biosensors in TDM holds great promise for enhancing the optimization of drug exposure in critically ill patients, offering the potential for improved outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.